Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Aura Biosciences reported strong financial results for Q4 and full year 2025, highlighted by accelerated enrollment in its global Phase 3 CoMpass trial for early choroidal melanoma with enrollment completion expected mid-2026 and topline data anticipated in the second half of 2027. The company is also progressing clinical trials in bladder cancer (…